Devita, Hellman, and Rosenberg's Cancer

LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14

606 Index

Disseminated intravascular

coagulation (DIC), risk factors

for, 519, 523

Disseminated peritoneal

adenomucinosis (DPAM),

488, 493

DLBCL.SeeDiffuse large B cell

lymphoma (DLBCL)

DLI.SeeDonor lymphocyte

infusion (DLI)

DLL4, 21, 30

DM.SeeDiabetes mellitus (DM)

DNA.SeeDeoxyribonucleic acid

(DNA)

DNA adducts, 34, 44

DNA damage repair

BRCA 1 protein function in, 35,

46

BRCA 2 protein function in, 35,

46

DNA, double-stranded breaks in,

86

DNA glycosylates, 12

usage of, 12

DNA polymerase/ligase, 12

DNA repair and ionizing radiation,

85, 90

DNMT3A mutation, 437, 443

Docetaxel, 198, 203, 213, 557

Donor lymphocyte infusion (DLI),

complications of, 528, 534

Dopamine, 136, 138

Dose-dense chemotherapy, 97, 102

Double-strand breaks (DSB), 6

Down syndrome, 413

Doxorubicin, for metastatic thyroid

carcinoma, 353, 360

DPAM.SeeDisseminated peritoneal

adenomucinosis (DPAM)

DPD.SeeDihydropyrimidine

dehydrogenase (DPD)

DSB.SeeDouble-strand breaks

(DSB)

Ductal cancer in situ (DCIS), 332

breast cancer and, 333, 343

Dying patients

delirium in, 562, 568

dyspnea in, 565, 570

insomnia in, 561, 567

Dysgeusia, 565, 571

Dyspnea, in dying patients, 565,

570

Early Breast Cancer Trialists’

Collaborative Group, 344

Eastern Collaborative Oncology

Group (ECOG), 418, 463

Eaton–Lambert myasthenic

syndrome, 217, 224

EBV.SeeEpstein-Barr virus (EBV)

EC.SeeEndothelial cell (EC)

E-cadherin, 22, 31

in esophagus cancer, 237

gastric cancer and, 233, 239

mutation testing, in gastric cancer,

232, 238–239

EC division and VEGF, 29

ECOG.SeeEastern Collaborative

Oncology Group (ECOG)

Ectopic ACTH production, 517,

522

E6, E7 viral proteins and HPV, 39,

51

E2F,2,8

EGFR.SeeEpidermal growth factor

receptor (EGFR)

EGFR-TK mutation, 97, 102

Electrocardiograms, 439, 445

and early detection of cardiac

dysfunction, 554, 559

Embryonal rhabdomyosarcoma

(RMS), 395, 405

Emergencies, oncologic, 503–508

Empiric antibiotic regimen, for

cancer patients with

meningitis, 542, 548

Employment rights of cancer

patients, Americans with

Disabilities Act of 1990 and,

574, 578

Endocrine system, cancer of,

349–363

Endometrial cancer

-catenin mutation in, 315, 323

BCL2 overexpression in, 315, 323

chemotherapy in, 321, 328, 329

diabetes mellitus and, 320, 327

estrogen therapy and, 327

HER2/neu amplification in, 315,

323

hysterectomy and, 320, 327

KRAS mutation in, 315, 323

Lynch syndrome and, 153, 159

obesity and, 62, 68, 320, 327

p53 mutations in, 315, 323

PTEN mutation in, 315, 323

radiation therapy in, 321,

327–328

recurrence of, 321, 328–329

risk factors for, 315, 320, 323,

327

serum CA-125 and, 321, 329

staging system of, 320, 328

treatment, cis-

platin/doxorubicin/paclitaxel

in, 321, 329

type I characteristics, 314, 323

type II characteristics, 314, 323

Endoscopy, benefits of, 177

Endothelial cell (EC), 20

Enlarged thymus glands treatment,

radiation in, 59, 64

EORTC.SeeEuropean

Organization for Research

and Treatment of Cancer

(EORTC)

EORTC 22845 trial, 389

EP.SeeEtoposide (EP)

Ependymoma, 387, 392

radiation therapy for, 386, 390

Epidermal growth factor receptor

(EGFR), 20, 95, 106, 195,

199, 205, 210

in esophagus cancer, 237

lung cancer and, 205, 210

Epidural anesthesia, 77, 81

Epidural local anesthetics, 570

Epothilones, 130

Epstein-Barr virus (EBV), 38, 50,

106, 111, 498

in Burkitt’s lymphoma, 106, 111

cancer and, 40, 52

in nasopharyngeal carcinoma,

106, 111

primary CNS lymphoma and,

384, 389

PTLD and, 543, 549

in T cell-lymphoma, 106, 111

ER.SeeEstrogen receptor (ER)

Erlotinib, 199, 208, 212

in NSCLC treatment, 207, 212

Erosive esophagitis, 547

Erythrocytosis, 253, 257

tumors associated with, 518, 522

Erythropoietin, 571

Esophageal adenocarcinoma, risk

factor of, 68

Esophageal cancer, 231, 238

achalasia and, 231, 238

and Barrett’s esophagus, 142, 145

capecitabine and, 234, 240

chemoradiotherapy in, 235,

240–241

E-cadherin expression in, 237

EGFR overexpression in, 237

FDG-PET in, 233, 240

gastroesophageal reflux disease

and, 142, 145

incidence rates of, 231

andN-nitrosamines, 43

oxaliplatin and, 234, 240

Plummer–Vinson syndrome and,

231, 238

p53 point mutation in, 237

preoperative radiotherapy and

chemoradiotherapy, 233,

239–240